CD137, implications in immunity and potential for therapy

Area of Science:

• Immunology
• Molecular Biology
• Oncology

Background:

• CD137 (4-1BB) is a T cell costimulatory molecule within the TNF receptor superfamily.
• Its ligand (CD137L) is expressed on antigen-presenting cells, mediating crucial immune interactions.

Purpose of the Study:

• To explore the dual role of CD137 modulation in immune responses.
• To evaluate the therapeutic potential of targeting the CD137 pathway in cancer and autoimmune diseases.

Main Methods:

• Review of preclinical studies and ongoing clinical trials involving agonistic and antagonistic anti-CD137/CD137L antibodies.
• Analysis of signaling pathways influenced by CD137 and CD137L interactions.

Main Results:

• Agonistic anti-CD137 antibodies enhance anti-tumor T cell responses in preclinical models and early clinical trials.
• Paradoxically, these same antibodies can ameliorate autoimmune diseases in specific contexts.
• Antagonistic anti-CD137L antibodies demonstrate efficacy in reducing disease severity in murine autoimmune models.

Conclusions:

• The CD137 pathway presents a complex therapeutic target with potential applications in both oncology and autoimmune disorders.
• Careful patient selection and strategic antibody design are crucial for safe and effective clinical application of CD137-targeting therapies.
• Further research is needed to elucidate the precise mechanisms governing the context-dependent effects of CD137 agonism.